Table 3.
Race/ Ethnic Group | Caucasian n = 558A |
African- American n = 93B |
Hispanic n = 73C |
p-value |
---|---|---|---|---|
Total Adverse Events,Mean # of events ± SD | 5.2 ± 4.0 | 2.9 ± 2.0 | 4.9 ± 3.0 | < 0.001 |
Adverse Events Definitely Not Study Drug Related, Mean # of events ± SD | 3.7 ± 3.3 | 1.5 ± 1.4 | 3.8 ± 3.0 | < 0.001 |
Opioid-positive Urine Test at Randomization, n(%) | 144 (36.7%) | 18 (31.0%) | 20 (41.7%) | 0.520 |
Any Drug-positive Urine Test at Randomization, n(%) | 260 (66.3%) | 37 (63.8%) | 33 (68.8%) | 0.862 |
Attrition during Buprenorphine administration, n(%) | 165 (29.6%) | 33 (35.5%) | 25 (34.3%) | 0.415 |
Buprenorphine dose at randomization, mean score ± SD | 20.4 ± 5.2 | 18.8 ± 5.9 | 21.2 ± 5.1 | 0.045 |
At randomization, the sample size is reduced to 392 for Urine test, 393 for buprenorphine dose.
At Randomization, the sample size is reduced to 58 for Urine test, 60 for buprenorphine dose.
At randomization, the sample size is reduced to 48 for Urine test, and buprenorphine dose.